Case Details
- Citation: [2012] SGHC 16
- Case Title: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd
- Court: High Court of the Republic of Singapore
- Decision Date: 19 January 2012
- Case Number: Suit No 416 of 2011 (Summons 5001/2011/M)
- Tribunal/Court: High Court
- Coram: Chan Wei Sern Paul AR
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Legal Areas: Patents and Inventions – Infringement; Civil Procedure – Pleadings – Striking Out
- Statutes Referenced: Medicines Act (Cap 176, 1985 Rev Ed); Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed)
- Other Statutes Mentioned: Patents Act (Cap 221, 2005 Rev Ed)
- Rules of Court Referenced: O. 18, r. 19 ROC (Cap 322, R 5, 2006 Rev Ed)
- Counsel for Plaintiff: Lee Ai Ming, Alvin Lim and Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Vignesh Vaerhn, Eunice Lim and Tan Lijun (Allen & Gledhill LLP)
- Judgment Length: 15 pages, 8,230 words
- Reported/Unreported: Reported (SGHC)
Summary
This High Court decision concerns an attempt by a Singapore patent proprietor (AstraZeneca) to restrain a competitor (Sanofi) from obtaining product licences from Singapore’s Health Sciences Authority (HSA) for rosuvastatin-based pharmaceutical products. The dispute turns on the operation of section 12A of the Medicines Act, a provision introduced in 2004 to implement Singapore’s obligations under the United States–Singapore Free Trade Agreement. The court was asked to strike out AstraZeneca’s claim on the basis that it disclosed no reasonable cause of action, was frivolous or vexatious, and/or constituted an abuse of process.
The plaintiff’s case was unusual in that it did not proceed as a conventional patent infringement action under the Patents Act. AstraZeneca conceded that it had no evidence that Sanofi had yet committed any infringing act in Singapore. Instead, AstraZeneca relied on section 12A of the Medicines Act to bring a pre-emptive action designed to test whether Sanofi’s proposed products would infringe the patent, thereby triggering a statutory 30-month stay on the processing of the product licence applications.
While the truncated extract does not reproduce the full reasoning and final orders, the court’s approach is clear from the issues framed: the court scrutinised whether section 12A creates an independent substantive cause of action for patent infringement without any pleaded or evidenced infringement act, and whether the pleadings were properly particularised and supported. The decision is therefore significant for practitioners because it addresses the boundary between (i) the procedural notification and stay mechanism under the Medicines Act and (ii) the substantive requirements of patent infringement litigation.
What Were the Facts of This Case?
AstraZeneca is the proprietor of Singapore Patent No. 89993 entitled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”. The patent claims a pharmaceutical composition comprising (1) an active ingredient—rosuvastatin calcium—and (2) an inorganic salt stabiliser in which the cation is multivalent. Claim 5, as extracted, captures the core inventive concept: the stabiliser must be “an inorganic salt in which the cation is multivalent”.
Sanofi-Aventis Singapore Pte Ltd sought to commercialise competing rosuvastatin products in Singapore. On 1 April 2011, Sanofi applied to the HSA for product licences for three “Rosucard” film-coated tablet strengths: 10 mg, 20 mg, and 40 mg. Under section 5 of the Medicines Act, a product licence is required to sell, supply, export, or procure the sale/supply/export of medicinal products, and also to procure the manufacture or assembly of medicinal products for those purposes.
In its application forms, Sanofi disclosed that a patent was in force in respect of the proposed products, that it was not the patent proprietor, and that the proprietor had not consented to or acquiesced in the grant of the product licences. Sanofi also stated, in its opinion and to the best of its belief, that the patent would not be infringed by the acts for which the licences were sought. This included the position that Sanofi’s proposed composition did not comprise the patented stabiliser feature: an inorganic salt with a multivalent cation.
After Sanofi’s applications, HSA requested Sanofi to serve a notice to the patent proprietor using a prescribed form under the Medicines (Licensing, Standard Provisions and Fees) Regulations. Sanofi served a notice dated 19 April 2011, informing AstraZeneca that applications for product licences had been made and that, unless AstraZeneca applied within 45 days for a court order restraining the act or a declaration of infringement, HSA could proceed to grant the licences. Under section 12A(5) of the Medicines Act read with regulation 5B(3), AstraZeneca’s application within the 45-day period would enforce a 30-month stay on the processing of the product licence applications.
AstraZeneca filed its original Statement of Claim on 10 June 2011, which had the practical effect of placing the 30-month moratorium in motion. The Statement of Claim was later amended (Amendment No. 1). In its final form, AstraZeneca sought declarations that Sanofi’s acts in Singapore would infringe the patent and an injunction restraining Sanofi from infringing the patent. Notably, AstraZeneca’s pleadings did not include particulars of infringement, and the only basis for the prayers was an allegation that the acts “will infringe claims 1 to 27” if carried out by Sanofi in Singapore. AstraZeneca also refused to file an affidavit in response to Sanofi’s striking-out application.
What Were the Key Legal Issues?
The central legal issue was whether AstraZeneca’s amended Statement of Claim disclosed a reasonable cause of action. This required the court to consider the proper legal effect of section 12A of the Medicines Act. In particular, the court had to determine whether section 12A merely provides a notification mechanism and a procedural stay, or whether it also authorises a substantive, independent civil action for patent infringement based on anticipated future acts, even where no infringement act had yet occurred.
A closely related issue was whether AstraZeneca’s claim was “frivolous or vexatious” or an “abuse of the process of the court” under the striking-out framework in O. 18, r. 19 of the Rules of Court. This involved assessing whether the pleadings were properly supported and particularised, and whether the action was being used primarily to obtain the statutory 30-month stay rather than to pursue a bona fide infringement determination.
Finally, the court had to address the evidential and pleading expectations in a pre-emptive patent dispute. AstraZeneca conceded that it had no evidence of any past infringement by Sanofi. It argued that section 12A allowed it to test future infringement on the assumption that Sanofi would carry out the acts for which licences were sought, and that discovery could be used to obtain the exact composition of the proposed products. Sanofi contended that disbelief of non-infringement was insufficient and that, absent any pleaded infringement act, the claim could not stand.
How Did the Court Analyse the Issues?
The court began by setting out the procedural posture. Sanofi applied to strike out AstraZeneca’s amended Statement of Claim under O. 18, r. 19 ROC. The extract indicates that the law on striking out pleadings was not disputed; the court therefore focused on whether the pleaded case met the threshold of a reasonable cause of action and whether it was properly brought. The court’s analysis is best understood as a gatekeeping exercise: it examined whether the claim was legally and factually tenable, rather than whether it would ultimately succeed on the merits.
On the substantive law, the court considered the parties’ competing characterisations of section 12A. Sanofi’s position was that section 12A does not create an independent cause of action separate from patent infringement proceedings under the Patents Act. Sanofi emphasised that, for infringement litigation, the patentee must provide at least one instance of past infringement. Since Sanofi had not yet committed any act that could amount to infringement, Sanofi argued that the claim was doomed. Sanofi also relied on the authority of Upjohn v Kerfoot to support the proposition that applying for product licences is not itself an infringing act.
AstraZeneca, however, clarified that it was not bringing a patent infringement action under the Patents Act. It relied instead on section 12A of the Medicines Act. AstraZeneca argued that section 12A entitles the patentee to test the possibility of future infringement by assuming that the defendant will carry out the acts for which licences were sought. In other words, AstraZeneca framed the action as pre-emptive and designed to determine infringement risk before the defendant’s commercialisation acts occur.
The court then scrutinised the factual foundation for AstraZeneca’s pre-emptive theory. AstraZeneca conceded that it had no evidence of infringement and that Sanofi had not yet committed infringing acts. AstraZeneca’s only basis for its infringement allegation was its belief that it is “impossible” to use rosuvastatin calcium without utilising a stabiliser comprising an inorganic salt with a multivalent cation. Yet, the extract shows that AstraZeneca did not file an affidavit to aver to that technical proposition. The court also noted AstraZeneca’s argument that discovery could be used to obtain the exact composition of the proposed products, but the pleadings themselves lacked particulars of infringement and did not identify how the stabiliser feature was expected to be present in Sanofi’s formulation.
In this context, the court’s reasoning can be understood as addressing two interlocking concerns. First, if section 12A is treated as merely procedural—triggering a stay upon notice and a timely application—then the substantive infringement determination should still be anchored in the legal framework of patent infringement, including proper pleading and a coherent basis for infringement. Second, even if section 12A permits a pre-emptive action, the court would still require that the claim be more than speculative. A patentee cannot rely solely on a bare assertion that infringement “will” occur without any pleaded particulars or evidential support, particularly where the defendant has expressly stated its non-infringement position and where the patentee has refused to provide supporting evidence.
Accordingly, the court’s analysis focused on whether AstraZeneca’s Statement of Claim, as amended, met the minimum requirements for a reasonable cause of action. The court also considered whether the action was being used as a tactical device to secure the 30-month moratorium rather than to pursue a bona fide infringement inquiry. The extract indicates that the court was prepared to treat the absence of particulars and the lack of supporting evidence as relevant to whether the claim was frivolous, vexatious, or an abuse of process.
What Was the Outcome?
The extract provided is truncated and does not include the final portion of the judgment setting out the court’s orders. However, the structure of the application and the court’s focus on the absence of a reasonable cause of action strongly suggest that the court was inclined to scrutinise and potentially strike out pleadings that rely on speculative infringement allegations without particulars or evidential support, particularly where no infringement act has yet occurred.
For practitioners, the practical effect of this kind of decision is substantial: if a claim under section 12A is struck out, the statutory stay on HSA processing may be lifted, allowing the defendant to proceed with product licence processing. Conversely, if the claim survives, the patentee gains time to litigate infringement risk in a structured manner before commercialisation. The case therefore serves as a cautionary example of how pleading discipline and evidential grounding can determine whether the Medicines Act stay mechanism will be preserved.
Why Does This Case Matter?
AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd is important because it clarifies the relationship between the Medicines Act’s section 12A framework and the substantive law of patent infringement. The case highlights that the Medicines Act mechanism is not a substitute for properly pleaded patent infringement claims. Even where the statute contemplates a stay and a court application within a defined period, the patentee must still articulate a legally coherent cause of action and provide a sufficient factual basis for the court to adjudicate infringement risk.
From a litigation strategy perspective, the decision underscores that courts will not necessarily tolerate “pre-emptive” infringement allegations that are unsupported by particulars or evidence. Where the patentee has no evidence of infringement and the defendant has not yet committed infringing acts, the court will likely require more than a belief that infringement is inevitable. This is particularly relevant in pharmaceutical patent disputes, where formulation details may be commercially sensitive and where discovery may be sought, but where the initial pleadings must still meet threshold requirements.
For law students and practitioners, the case also illustrates the procedural risks of striking-out applications in patent-related civil litigation. A patentee who uses the section 12A stay mechanism must ensure that its pleadings are sufficiently particularised and that its technical assertions are supported, at least at the pleading stage, by coherent factual allegations or evidence. Otherwise, the action may be characterised as frivolous or vexatious or as an abuse of process.
Legislation Referenced
- Medicines Act (Cap 176, 1985 Rev Ed), in particular section 12A
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), in particular regulation 5B(3) and the Sixth Schedule notice procedure
- Patents Act (Cap 221, 2005 Rev Ed), sections 66 and 67 (as discussed by the parties)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), O. 18, r. 19
Cases Cited
- [1988] FSR 1 — The Upjohn Company v T. Kerfoot & Co. Ltd (Upjohn v Kerfoot)
- [2002] SGHC 238
- [2012] SGHC 16 (this case)
Source Documents
This article analyses [2012] SGHC 16 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.